Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity

Int J Mol Sci. 2017 Jun 20;18(6):1267. doi: 10.3390/ijms18061267.


Centrosome aberrations have been implicated in the development and progression of breast cancer. Our previous worked show that centrosomal protein 70 (Cep70) regulates breast cancer growth and metastasis. However, it remains elusive whether Cep70 is implicated in the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. Here we provide evidence that Cep70 is a mediator of paclitaxel sensitivity in breast cancer. Cell proliferation assays show that Cep70 expression correlates with paclitaxel sensitivity in breast cancer cell lines. In addition, paclitaxel sensitivity varies when altering Cep70 expression level. Mechanistic studies reveal that Cep70 interacts with tubulin, and promotes the ability of paclitaxel to stimulate microtubule assembly. These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer.

Keywords: Cep70; breast cancer; microtubule; paclitaxel sensitivity.

MeSH terms

  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism
  • Cell Cycle Proteins / drug effects*
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism*
  • Cell Line, Tumor / drug effects
  • Cell Proliferation / drug effects
  • Female
  • Gene Knockdown Techniques
  • HEK293 Cells
  • Humans
  • MCF-7 Cells
  • Microtubule-Associated Proteins / drug effects*
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / metabolism*
  • Microtubules / metabolism
  • Paclitaxel / pharmacology*
  • Tubulin / metabolism


  • Cell Cycle Proteins
  • Cep70 protein, human
  • Microtubule-Associated Proteins
  • Tubulin
  • Paclitaxel